逐瘀通脉滴丸药理药效学研究

目的:研究逐瘀通脉滴丸同逐瘀通脉胶囊、复方丹参滴丸的药理药效学。方法:采用盐酸肾上腺素与冰水浴交替制备法制备动物模型,采用毛细管法、体外自然溶解法、紫外分光光度计比浊法测定逐瘀通脉滴丸、逐瘀通脉胶囊及复方丹参滴丸对实验大鼠全血粘度、血液凝块溶解率、血小板聚集功能的影响。结果:逐瘀通脉滴丸对降低实验大鼠全血粘度、抑制体外血栓形成及抑制血小板聚集功能效果优于逐瘀通脉胶囊和复方丹参滴丸。结论:逐瘀通脉滴丸可用于治疗高粘滞血症、血瘀症、血栓。疗效优于逐瘀通脉胶囊和复方丹参滴丸。

坚持自主研发：把抗癌药做到“顶尖”——专访抗癌药的药理药效学专家丁健院士

“人要始终摆正自己的位置，不要把个人无限地放大。如果把科学比作大海的话，那么我所取得的成绩不过相当于大海中的一滴水。”

消定膏的药效学实验及临床应用概况

就近年来消定膏药效学和现代临床运用的相关研究文献进行检索,并从抗炎、皮肤过敏反应以及急性软组织损伤、膝关节创伤性滑膜炎、跗骨窦综合征,痛风性关节炎、膝关节镜术后肿胀、踝关节扭伤几方面分析整理,以期为消定膏的临床应用提供理论依据。

消风散的药理药效研究及临床应用概况

检索近年来消风散及其加减方药效学和现代临床运用的研究文献,分析整理,探讨消风散目前药效学及其现代临床运用研究的概况。消风散具有抗炎、抗过敏、止痒、抗变态反应及免疫调节的作用。原方或其加减方现代临床常用于风疹、荨麻疹、湿疹、过敏性皮炎、药物性皮炎、神经性皮炎等皮肤科疾病,随之药理药效研究的不断深入,已经逐渐在眼科、口腔科、五官科、肛肠科、肾内科、妇产科等多个学科疾病的治疗中运用,并且取得满意的效果。期待消风散能在其它Ⅳ型变态反应疾病以及某些自身免疫性疾病引起的炎症反应中发挥作用。

Study on the compatibility principle of Wutou Decoction based on network pharmacology

Objective To investigate the underlying drug enhancement mechanisms of the Chuanwu(Aconiti Radix)and Huangqi(Astragali Radix)combination and toxicity reduction of Chuan-wu combined with Gancao(Glycyrrhizae Radix et Rhizoma)in Wutou Decoction(乌头汤,WTD),and to elucidate the compatibility principle.Methods The active compounds and potential effective targets of the selected combinations were retrieved from the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform(TCMSP)and Traditional Chinese Medicines Integrated Database(TCMID).The toxicity of Chuanwu(Aconiti Radix)was investigated by selecting all five toxic compounds from the literature and the TCMSP database,and obtaining their targets through SwissTargetPrediction.Targets related to rheumatoid arthritis(RA)were searched using Dis-GeNET,GenCards,and Online Mendelian Inheritance in Man(OMIM).Mutual targets between the drug pairs and RA were selected as potential RA therapy targets.The medicinally active compound-target network was constructed using Cytoscape 3.9.0.Gene ontology(GO)term enrichment and Kyoto Encyclopedia of Genes and Genomes(KEGG)pathway enrich-ment were performed using the Database for Annotation,Visualization,and Integrated Dis-covery(DAVID)platform.Results We obtained 191 active compound targets for Gancao(Glycyrrhizae Radix et Rhizoma),171 for Huangqi(Astragali Radix),and 103 for Chuanwu(Radix Aconiti)(hypo-aconitine’s target was obtained through literature and SwissTargetPrediction).A total of 5872 genes were obtained for RA.A drug-active compound-target network involving 13 effect-en-hancing and nine toxicity reduction targets was constructed.PGR was the main effect en-hancement target,and KCNH2 was the main toxicity reduction target.The effect-enhancing targets were related to 23 GO terms(such as positive regulation of transcription from RNA polymerase II promoter,steroid hormone-mediated signaling pathway,plasma membrane,and protein binding)(P<0.01),and 13 KEGG pathways related to synergism[such as estro-gen signaling pathway,cholinergic synapse,and phosphatidylinositol 3-kinase/protein kinase B(PI3K/Akt)signaling pathway].The toxicity reduction targets were related to 28 GO terms(mainly involes G-protein coupled receptor signaling pathway,plasma membrane,and drug binding)(P<0.01),and five KEGG pathways related to toxicity reduction(cholinergic syn-apse,calcium signaling pathway,regulation of actin cytoskeleton,neuroactive ligand-recept-or interaction,and serotonergic synapse).Conclusion The combination of Chuanwu(Aconiti Radix)and Huangqi(Astragali Radix)plays an important effect-enhancing role in WTD and involves the estrogen and PI3K/Akt sig-naling pathways,with PGR as the core.The Chuanwu(Aconiti Radix)and Gancao(Gly-cyrrhizae Radix et Rhizoma)combination decreases toxicity in WTD and is associated with the cholinergic synapse and calcium signaling pathways,with KCNH2 as the core.

三七通舒胶囊全国临床应用有奖征文评选获奖结果

三七通舒胶囊为国家中药Ⅱ类新药，具有活血化淤、活络通脉；抗血小板聚集，抗血栓形成的功能，为交流探讨三七通舒胶囊的临床应用以及进一步开展三七通舒胶囊的药理药效学研究，成都华神集团股份有限公司制药厂与中华神经科杂志、中国神经精神疾病杂志编辑部于2007年1月15日联合举办的三七通舒胶囊全国临床应用有奖征文活动现已结束。经过专家评审，现将征文评选获奖结果刊登如下（仅刊登文章第一作者）。